Impact Of Hospital-Acquired Infections On The Catheter-Related Bloodstream Infection Market Driver: A Major Catalyst in the Evolution of the Catheter-Related Bloodstream Infection Market in 2025

Which drivers are expected to have the greatest impact on the over the catheter-related bloodstream infection market's growth?
The catheter-related bloodstream infection market is anticipated to expand due to the growing incidence of hospital-acquired infections. These infections are contracted by patients while they are receiving treatment for other ailments in a healthcare facility. They typically develop 48 hours or more post-admission. The escalation in hospital-acquired infections can be linked to several aspects such as antimicrobial resistance, insufficient measures for infection control, and patient susceptibility. Catheter-related bloodstream infections substantially contribute to hospital-acquired infections because of their potential to invade and allow microbial colonization, thus posing a threat to patients with indwelling catheters. For example, according to data from the National Library of Medicine, a prominent US biomedical library, in January 2023, the global rate of healthcare-associated infection (HAI) stood at 0.14%, showing an annual increase of 0.06%. Therefore, the surging incidence of hospital-acquired infections will promote the expansion of the catheter-related bloodstream infection market.

Get Your Catheter-Related Bloodstream Infection Market Report Here:
https://www.thebusinessresearchcompany.com/report/catheter-related-bloodstream-infection-global-market-report

What is the future CAGR of the catheter-related bloodstream infection market, and how will it impact industry expansion?
The market size for catheter-related bloodstream infections has experienced robust growth in recent times. The market value is expected to increase from $1.53 billion in 2024 to $1.62 billion in 2025, courtesy of a compound annual growth rate (CAGR) of 6.2%. This growth during the historic period can be credited to factors like a surge in the occurrence of chronic diseases, improved awareness and education, an increase in hospital-acquired infections, an expanding elderly population, and the implementation of superior infection control programs within hospital and healthcare environments.

In the coming years, it is anticipated that the market size for catheter-related bloodstream infection will experience significant growth. By 2029, it is projected to expand to $2.05 billion, with a compound annual growth rate (CAGR) of 6.0%. This projected growth in the forecast period can be attributed to factors such as increasing healthcare-associated infections (hais), heightened awareness and training, improved training programs concerning infection control practices, development of healthcare infrastructure, growth in the aging population, and supportive government policies and initiatives. The forecast period will also witness major trends such as biomaterial advancements, intelligent catheter technology, the creation of more effective catheter lock solutions with sophisticated antimicrobial characteristics, breakthroughs in catheter sterilization processes, and the initiation of automated flushing systems.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16646&type=smp

What are the most significant trends transforming the catheter-related bloodstream infection market today?
Leading firms in the market for catheter-related bloodstream infection are focusing on creating advanced catheter lock solutions, with the aim of amplifying infection prevention measures and bettering patient outcomes. These solutions involve the use of a fluid introduced into the catheter to shield against infection and ensure the catheter remains open for repeat use. An example of this emerged in November 2023, when CorMedix Inc., a biopharmaceutical enterprise from the US centered on the development and sale of therapeutic products, obtained approval from the US Food and Drug Administration for their product DefenCath (taurolidine and heparin) catheter lock solution. This solution, designed for adult patients suffering from kidney failure who are also on chronic hemodialysis via a central venous catheter (CVC), is both antimicrobial and antifungal. It is specially crafted to lessen the instances of catheter-related bloodstream infections (CRBSIs), and it blends the anticoagulation abilities of heparin with the widespread antimicrobial attributes of taurolidine.

Which key market segments comprise the catheter-related bloodstream infection market and drive its revenue growth?
The catheter-related bloodstream infection market covered in this report is segmented -

1) By Treatment: Antibiotic Lock Therapy, Anti-Microbial Agents
2) By Source Of Infection Or Causative Agents: Staphylococcus Aureus, Acinetobacter Baumannii, Escherichia Coli (E. Coli), Klebsiella Pneumoniae (K. Pneumonia), Candida Species (Candida Sp.), Pseudomonas Aeruginosa (P. Aeruginosa), Other Source Of Infection Or Causative Agents
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Antibiotic Lock Therapy: Catheter Lock Solutions (Antibiotic-based), Combination Antibiotic Lock Therapy
2) By Anti-Microbial Agents: Antibiotics, Antifungal Agents, Antiseptic Agents

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16646

North America was the largest region in the catheter-related bloodstream infection market in 2023. The regions covered in the catheter-related bloodstream infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the leading players fueling growth in the catheter-related bloodstream infection market?
Major companies operating in the catheter-related bloodstream infection market are Pfizer Inc., Johnson & Johnson Services Inc., Novartis AG, 3M Company, Eli Lilly and Company, Fresenius Medical Care AG & Co. KGaA, Becton Dickinson and Company, Viatris Inc., B. Braun Medical Inc., Aurobindo Pharma Limited, Lupin Ltd., Xellia Pharmaceuticals Ltd., SteriMax Inc., Geistlich Pharma AG, Bactiguard AB, Hetero Healthcare Ltd., TauroPharm GmbH, Advacare Pharma, Citus Pharmaceuticals Inc., CorMedix Inc., JoinHub Pharma LLP, IntegraDose Compounding Services LLC

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=16646&type=smp

What Is Covered In The Catheter-Related Bloodstream Infection Global Market Report?

•Market Size Forecast: Examine the catheter-related bloodstream infection market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the catheter-related bloodstream infection market for a structured understanding.
•Key Players Overview: Analyze major players in the catheter-related bloodstream infection market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the catheter-related bloodstream infection market.
•Segment Contributions: Evaluate how different segments drive overall growth in the catheter-related bloodstream infection market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the catheter-related bloodstream infection market.
•Industry Challenges: Identify potential risks and obstacles affecting the catheter-related bloodstream infection market.
•Competitive Landscape: Review strategic developments in the catheter-related bloodstream infection market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.